

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**CASSELMAN, WILLIAM E. II**

2. Address:

PO BOX 156, ALDIE, VA 20105

3. Principal place of business (if different from line 2):

4. Contact Name: WILLIAM E. CASSELMAN, II

Telephone: 703-327-3116

E-mail (optional): weclawfirm@aol.com

Senate ID #: 8442-101

House ID #: 30815004

7. Client Name:  Self

**KEDDEM BIOSCIENCE LTD.**

### TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: \_\_\_\_\_ 11. No Lobbying Activity:

### INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

#### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): \_\_\_\_\_

#### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only  
 **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
 **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: CASSELMAN, WILLIAM E. II Client Name: KEDDEM BIOSCIENCE LTD.

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: DEF (one per page)

16. Specific lobbying issues:

Funding of research and development activities involving small molecule drugs for defense purposes.

17. House(s) of Congress and Federal agencies contacted:

Defense Advanced Research Projects Agency

18. Name of each individual who acted as a lobbyist in this issue area:

Name: WILLIAM E. CASSELMAN, II

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Obtaining of grant, contract or cooperative agreement.

Registrant Name: CASSELMAN, WILLIAM E. II Client Name: KEDDEM BIOSCIENCE LTD.

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

Funding of research and development involving small molecule drugs for medical purposes.

17. House(s) of Congress and Federal agencies contacted:  
Defense Advanced Research Projects Agency

18. Name of each individual who acted as a lobbyist in this issue area:

Name: WILLIAM E. CASSELMAN, II  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.  
Obtaining of grant, contract or cooperative agreement.

Registrant Name: CASSELMAN, WILLIAM E. II Client Name: KEDDEM BIOSCIENCE LTD.

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

Funding of research and development activities involving small molecule drugs for commercial and government purposes.

17. House(s) of Congress and Federal agencies contacted:  
Defense Advanced Research Projects Agency

18. Name of each individual who acted as a lobbyist in this issue area:

Name: WILLIAM E. CASSELMAN, II  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.  
Obtaining of grant, contract or cooperative agreement.

Signature: ON FILE Date: Aug 10, 2006

Printed Name and Title: WILLIAM E. CASSELMAN, II - ATTORNEY AT LAW